When mutants gain new powers: News from the mutant p53 field

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M., van de Rijn, M., Jeffrey, S., et al. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.191367098 · Cited by 11,695 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161 · see citing works

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814 · see citing works

Impact of mutant p53 functional properties on <i>TP53</i> mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · see citing works

Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms

Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514 · see citing works

Gene-Expression Signatures in Breast Cancer

Sotiriou, C. P., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,482 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1× · see citing works

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,380 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

mdm2 expression is induced by wild type p53 activity.

Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1× · see citing works

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L. A., Ploner, A., Yudi Pawitan, Y., Hall, P. N., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,269 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

Decision making by p53: life, death and cancer

Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,063 · see citing works

Increased expression of mutant forms of p53 oncogene in primary lung cancer

Iggo, R. D., Bártek, J., Lane, D. P., Gatter, K. C., Harris, A. L., & Bártek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,030 · see citing works

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works

MicroRNAs and Cancer: Short RNAs Go a Long Way

Ventura, A., & Jacks, T. (2009) · Cell · doi:10.1016/j.cell.2009.02.005 · Cited by 893 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 877 · see citing works

TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck

Poeta, M. L., Manola, J. B., Goldwasser, M. A., Forastiere, A. A., Benoit, N. E., Califano, J. A., Ridge, J. A., Goodwin, J. W., Kenady, D. E., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 818 · see citing works

Phosphotyrosine interactome of the ErbB‐receptor kinase family

Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753 · see citing works

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

Aas, T., Børresen‐Dale, A., Geisler, S. B., Smith‐Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736 · see citing works

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 731 · see citing works

Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53

Chin, K., Ueda, K., Pastan, I. H., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726 · see citing works

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721 · see citing works

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

Eliyahu, D., Raz, A., Gruß, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 706 · see citing works

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669 · see citing works

p53 polymorphisms: cancer implications

Whibley, C., Pharoah, P. D. P., & Hollstein, M. C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2584 · Cited by 667 · see citing works

Assessing TP53 status in human tumours to evaluate clinical outcome

Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659 · see citing works

Common markers of proliferation

Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650 · cited 1× · see citing works

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612 · see citing works

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J. C. S., Klaar, S., Eyfjord, J. E., Theillet, C. G., Rodríguez, C., Lidereau, R., Bièche, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 590 · see citing works

Rescuing the function of mutant p53

Bullock, A. N., & Fersht, A. R. (2001) · Nature reviews. Cancer · doi:10.1038/35094077 · Cited by 565 · see citing works

p53 Antibodies in the sera of patients with various types of cancer: a review.

Soussi, T. (2000) · PubMed · Cited by 555 · see citing works

Growth regulation of a cellular tumour antigen, p53, in nontransformed cells

Reich, N. C., & Levine, A. J. (1984) · Nature · doi:10.1038/308199a0 · Cited by 517 · see citing works

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Bártek, J., Bártková, J., Vojtěšek, B., Stašková, Z., Lukáš, J., Rejthar, A., Kovařík, J., Midgley, C. A., Gannon, J., & Lane, D. P. (1991) · PubMed · Cited by 506 · see citing works

Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family

Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R. T., Crowley, D. G., Yang, A., McKeon, F., & Jacks, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.019 · Cited by 499 · see citing works

Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes.

Aguilar, F., Hussain, S. P., & Cerutti, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8586 · Cited by 490 · see citing works

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464 · see citing works

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

Bergh, J. C. S., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 459 · see citing works

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445 · see citing works

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 442 · see citing works

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439 · see citing works

Control of autophagy by oncogenes and tumor suppressor genes

Maiuri, M. C., Tasdemir, E., Criollo, A., Morselli, E., Vicencio, J. M., Carnuccio, R., & Kroemer, G. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.131 · Cited by 433 · see citing works

Structure–function–rescue: the diverse nature of common p53 cancer mutants

Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 430 · see citing works

GermlineTP53 mutations and Li-Fraumeni syndrome

Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 429 · see citing works

Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas

黒瀬, 圭., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418 · see citing works

Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · see citing works

p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells

Como, C. J. D., Gaiddon, C., & Prives, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417 · see citing works

Rhabdomyosarcoma in Children: Epidemiologic Study and Identification of a Familial Caneer Syndrome

Li, F. P., & Fraumeni, J. F. (1969) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/43.6.1365 · Cited by 397 · see citing works

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.

Werner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8318 · Cited by 370 · see citing works

Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum

Kress, M., May, E., Cassingena, R., & May, P. (1979) · Journal of Virology · doi:10.1128/jvi.31.2.472-483.1979 · Cited by 359 · see citing works

The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint

Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 356 · see citing works

Nuclear Accumulation of p53 Protein Is Mediated by Several Nuclear Localization Signals and Plays a Role in Tumorigenesis

Shaulsky, G., Goldfinger, N., Ben‐Ze'ev, A., & Rotter, V. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565-6577.1990 · Cited by 346 · see citing works

TP53 mutation in colorectal cancer

Iacopetta, B. J. (2003) · Human Mutation · doi:10.1002/humu.10175 · Cited by 345 · see citing works

Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets

Dong, S. M., Traverso, G., Johnson, C., Geng, L., Favis, R., Boynton, K. A., Hibi, K., Goodman, S. N., D’Allessio, M., Paty, P. B., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.11.858 · Cited by 338 · see citing works

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

Blagosklonny, M. V., Toretsky, J. A., Bohen, S. P., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 315 · see citing works

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding

MIDGLEY, C. A., & Lane, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201459 · Cited by 313 · see citing works

Breast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases

Patócs, A., Zhang, L., Xu, Y., Weber, F., Caldés, T., Mutter, G. L., Platzer, P., & Eng, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071825 · Cited by 297 · see citing works

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

Sur, S., Pagliarini, R. A., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 293 · see citing works

TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer

Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291 · see citing works

Mutant p53 protein localized in the cytoplasm inhibits autophagy

Morselli, E., Tasdemir, E., Maiuri, M. C., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 279 · see citing works

Mutant p53: an oncogenic transcription factor

Strano, S., Dell’Orso, S., Agostino, S. D., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 270 · see citing works

The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation

Esser, C., Scheffner, M., & Höhfeld, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501574200 · Cited by 261 · see citing works

p63 and p73 in human cancer: defining the network

DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 261 · see citing works

Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene

Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 245 · see citing works

Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes

Milner, J., Medcalf, E., & Cook, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243 · see citing works

Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines.

Hinds, P. W., Finlay, C. A., Frey, A. B., & Levine, A. J. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2863 · Cited by 232 · see citing works

p53 alterations in human cancer: more questions than answers

Soussi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210280 · Cited by 232 · see citing works

Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families

Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230 · see citing works

Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array

Ahrendt, S. A., Halachmi, S., Chow, J. T., Li, W., Halachmi, N., Yang, S. C., Wehage, S. L., Jen, J., & Sidransky, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7382 · Cited by 228 · see citing works

Ubiquitination and Degradation of Mutant p53

Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223 · see citing works

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T., & Haferlach, C. (2008) · Leukemia · doi:10.1038/leu.2008.274 · Cited by 207 · see citing works

Transcription regulation by mutant p53

Weisz, L., Oren, M., & Rotter, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207 · see citing works

The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent

Whitesell, L. J., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., & Cook, P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1517 · Cited by 206 · see citing works

Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters

Imbriano, C., Gurtner, A., Cocchiarella, F., Agostino, S. D., Basile, V., Gostissa, M., Dobbelstein, M., Sal, G. D., Piaggio, G., & Mantovani, R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3737-3751.2005 · Cited by 205 · see citing works

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202 · see citing works

Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome

Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200 · see citing works

Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma

Batchelor, T. T., Betensky, R. A., Esposito, J. M., Pham, L.-D. D., Dorfman, M. V., Piscatelli, N., Jhung, S., Rhee, D. K., & Louis, D. N. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0841-3 · Cited by 200 · see citing works

Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells

Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M. L., Levrero, M., Strano, S., Gorgoulis, V. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2425 · Cited by 198 · see citing works

Activation of c- myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain

Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194 · see citing works

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

Young, K. H., Leroy, K., Møller, M. B., Colleoni, G. W. B., Sánchez‐Beato, M., Kerbauy, F. R., Haïoun, C., Eickhoff, J. C., Young, A. H., Gaulard, P., et al. (2008) · Blood · doi:10.1182/blood-2008-01-129783 · Cited by 191 · see citing works

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Кочетков, Д. В., Strom, E., Frolova, E. I., Kovriga, I. E., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191 · see citing works

A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma

Salvatore, G., Nappi, T. C., Salerno, P., Jiang, Y., Garbi, C., Ugolini, C., Miccoli, P., Basolo, F., Castellone, M. D., Cirafici, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1887 · Cited by 186 · see citing works

Chaperone-dependent stabilization and degradation of p53 mutants

Müller, P., Hrstka, R., Coomber, D., Lane, D. P., & Vojtěšek, B. (2008) · Oncogene · doi:10.1038/sj.onc.1211010 · Cited by 183 · see citing works

Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

Li, Y., & Prives, C. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210311 · Cited by 174 · see citing works

Hsp90: A Novel Target for Cancer Therapy

Solit, D. B., & Rosen, N. X. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 171 · see citing works

Molecular Basis for Heterogeneity of the Human p53 Protein

Harris, N., Brill, E., Shohat, O., Prokocimer, M., Wolf, D., Arai, N., & Rotter, V. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4650 · Cited by 171 · see citing works

Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50

Rotter, V., Witte, O. N., Coffman, R., & Baltimore, D. (1980) · Journal of Virology · doi:10.1128/jvi.36.2.547-555.1980 · Cited by 168 · see citing works

Gene expression patterns associated with p53 status in breast cancer

Troester, M. A., Herschkowitz, J. I., Oh, D. S., He, X., Hoadley, K. A., Barbier, C., & Perou, C. M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-276 · Cited by 168 · see citing works

p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells.

Rotter, V. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.9.2613 · Cited by 161 · see citing works

Recent advances in p53 research: an interdisciplinary perspective

Olivier, M., Petitjean, A., Marcel, V., Pétré, A., Mounawar, M., Plymoth, A., de Fromentel, C. C., & Hainaut, P. L. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.69 · Cited by 161 · see citing works

TP53 and ovarian cancer

Schuijer, M., & Berns, E. M. J. J. (2003) · Human Mutation · doi:10.1002/humu.10181 · Cited by 161 · see citing works

Association of breast cancer outcome with status of p53 and MDM2 SNP309.

Boersma, B., Howe, T. M., Goodman, J., Yfantis, H., Lee, D. H., Chanock, S., & Ambs, S. (2006) · Journal of the National Cancer Institute · doi:10.1093/jnci/djj245 · Cited by 160 · see citing works

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160 · see citing works

p53‐repressed miRNAs are involved with E2F in a feed‐forward loop promoting proliferation

Brosh, R., Shalgi, R., Liran, A., Landan, G., Korotayev, K., Nguyen, G. H., Enerly, E., Johnsen, H., Buganim, Y., Solomon, H., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.65 · Cited by 152 · see citing works

Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression

Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 149 · see citing works

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · see citing works

TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance

PELLER, S., & Rotter, V. (2003) · Human Mutation · doi:10.1002/humu.10190 · Cited by 141 · see citing works

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140 · see citing works

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139 · see citing works

Targeting p53 for enhanced radio- and chemo-sensitivity

Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 134 · see citing works

Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.

Shaulsky, G., Goldfinger, N., & Rotter, V. (1991) · PubMed · Cited by 133 · see citing works

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123 · see citing works

Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.

Lin, J., Teresky, A. K., & Levine, A. J. (1995) · PubMed · Cited by 123 · see citing works

Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes

Scian, M. J., Stagliano, K. E., Deb, D., Ellis, M. A., Carchman, E. H., Das, A., Valerie, K. C., Deb, S. P., & Deb, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207553 · Cited by 117 · see citing works

Modulation of Gene Expression by Tumor-Derived p53 Mutants

Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117 · see citing works

Cancer chemoresistance: The relationship between p53 and multidrug transporters

Bush, J., & Li, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10226 · Cited by 116 · see citing works

Regulation of p53 Nuclear Export through Sequential Changes in Conformation and Ubiquitination

Nie, L., Sasaki, M. M., & Maki, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610515200 · Cited by 114 · see citing works

Heat Shock Protein 84 Forms a Complex with Mutant p53 Protein Predominantly within a Cytoplasmic Compartment of the Cell

Sepehrnia, B., Paz, I. B., Dasgupta, G., & Momand, J. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15084 · Cited by 114 · see citing works

Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma

Young, K. H., Weisenburger, D. D., Davé, B. J., Smith, L. M., Sanger, W. G., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R. D., Ott, G., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072082 · Cited by 111 · see citing works

Mutant p53 Induces the GEF-H1 Oncogene, a Guanine Nucleotide Exchange Factor-H1 for RhoA, Resulting in Accelerated Cell Proliferation in Tumor Cells

Mizuarai, S., Yamanaka, K., & Kotani, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4629 · Cited by 111 · see citing works

p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway

Хромова, Н. В., Kopnin, P., Степанова, Е. В., Agapova, L. S., & Kopnin, B. P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.049 · Cited by 110 · see citing works

A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patients

Alsner, J., Jensen, V., Kyndi, M., Offersen, B. V., Vu, P., Børresen‐Dale, A., & Overgaard, J. (2008) · Acta Oncologica · doi:10.1080/02841860802047411 · Cited by 107 · see citing works

PTEN and p53: Who will get the upper hand?

Trotman, L. C., & Pandolfi, P. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00022-9 · Cited by 105 · see citing works

Restoration of p53 to limit tumor growth

Wang, W., & El‐Deiry, W. S. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f31d6f · Cited by 104 · see citing works

Transcriptional activities of mutant p53: When mutations are more than a loss

Kim, E. L., & Deppert, W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20271 · Cited by 102 · see citing works

Relationship between genetic alterations and prognosis in sporadic colorectal cancer

Chang, S., Lin, J.-K., Yang, S. H., Wang, H., Li, A. F., & Chi, C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21563 · Cited by 101 · see citing works

Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents

Rotter, V., Boss, M. A., & Baltimore, D. (1981) · Journal of Virology · doi:10.1128/jvi.38.1.336-346.1981 · Cited by 100 · see citing works

Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil

Pugacheva, E. N., Ivanov, A. V., Kravchenko, J. E., Kopnin, B. P., Levine, A. J., & Chumakov, P. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205704 · Cited by 99 · see citing works

The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer

Bull, S. B., Özçelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A. J., Pritchard, K. I., Tzontcheva, A., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.128 · Cited by 99 · see citing works

Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene

Tõnisson, N., Zernant, J., Kurg, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082100599 · Cited by 97 · see citing works

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations

Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95 · see citing works

Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma

Lee, Y. I., Lee, S., Das, G. C., Park, U. S., Park, S. M., & Lee, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203694 · Cited by 94 · see citing works

P53 transformation‐related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non‐transformed fibroblasts.

Rotter, V., Abutbul, H., & Ben‐Ze'ev, A. (1983) · The EMBO Journal · doi:10.1002/j.1460-2075.1983.tb01543.x · Cited by 94 · see citing works

Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival

Jain, A. N., Chin, K., Børresen‐Dale, A., Erikstein, B., Lønning, P. E., Kaaresen, R., & Gray, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151241198 · Cited by 93 · see citing works

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy

Bossi, G., Marampon, F., Maor-Aloni, R., ZANI, B. M., Rotter, V., Oren, M., Strano, S., Blandino, G., & Sacchi, A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6161 · Cited by 92 · see citing works

Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis

Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., & Rotter, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4163 · Cited by 87 · see citing works

Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration

Ruano, Y., Ribalta, T., de Lope, Á. R., Campos‐Martín, Y., Fiaño, C., Pérez-Magán, E., Hernández-Moneo, J.-L., Mollejo, M., & Meléndez, B. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcp64ybdvctirwv · Cited by 82 · see citing works

Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells

Lin, K., Rockliffe, N., Johnson, G. G., Sherrington, P. D., & Pettitt, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210893 · Cited by 78 · see citing works

Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function

Yan, W., & Chen, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900994200 · Cited by 77 · see citing works

TP53 and head and neck neoplasms

Blons, H., & Laurent‐Puig, P. (2003) · Human Mutation · doi:10.1002/humu.10171 · Cited by 77 · see citing works

Mutant p53 proteins bind DNA in a DNA structure-selective mode

hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76 · see citing works

Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences

Brázdová, M., Quante, T., Tögel, L., Walter, K., Loscher, C., Tichý, V., Činčárová, L., Deppert, W., & Tolstonog, G. V. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1085 · Cited by 72 · see citing works

The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation

Tabach, Y., Milyavsky, M., Shats, I., Brosh, R., Zuk, O., Yitzhaky, A., Mantovani, R., Domany, E., Rotter, V., & Pilpel, Y. (2005) · Molecular Systems Biology · doi:10.1038/msb4100030 · Cited by 72 · see citing works

p53 Missense Mutations in Microdissected High-Grade Ductal Carcinoma In Situ of the Breast

Done, S. J., Eskandarian, S., Bull, S. B., Redston, M. S., & Andrulis, I. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.700 · Cited by 71 · see citing works

Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II

Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., & Rotter, V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00374-07 · Cited by 70 · see citing works

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs

Agostino, S. D., Cortese, G., Monti, O., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.21.6995 · Cited by 70 · see citing works

25 Years of p53 Research

Hainaut, P. L., & Wiman, K. G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6 · Cited by 67 · see citing works

Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival

Bartel, F., Jung, J., Böhnke, A., Gradhand, E., Zeng, K., Thomssen, C., & Hauptmann, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1192 · Cited by 67 · see citing works

Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations

Yan, W., Liu, G., Scoumanne, A., & Chen, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0810 · Cited by 64 · see citing works

Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma

Burke, L. M., Flieder, D. B., Guinee, D. G., Brambilla, E., Freedman, A. N., Bennett, W. P., Jones, R. T., Borkowski, A., Caporaso, N. A., Fleming, M. V., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.232.11.1 · Cited by 64 · see citing works

Family Feud in Chemosensitvity: p73 and Mutant p53

Irwin, M. S. (2004) · Cell Cycle · doi:10.4161/cc.3.3.768 · Cited by 63 · see citing works

Gain of Oncogenic Function of p53 Mutants Induces Invasive Phenotypes in Human Breast Cancer Cells by Silencing CCN5/WISP-2

Dhar, G., Banerjee, S., Dhar, K., Tawfik, O. W., Mayo, M. S., VanVeldhuizen, P. J., & Banerjee, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0316 · Cited by 62 · see citing works

p16INK4a modulates p53 in primary human mammary epithelial cells.

Zhang, J., Pickering, C. R., Holst, C. R., Gauthier, M. L., & Tlsty, T. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1594 · Cited by 60 · see citing works

Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

Haupt, S., Agostino, S. D., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, G., & Haupt, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4010 · Cited by 59 · see citing works

Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.

Loging, W., & Reisman, D. (1999) · PubMed · Cited by 58 · see citing works

Transcriptional functionality of germ line p53 mutants influences cancer phenotype

Monti, P., Ciribilli, Y., Jordan, J., Menichini, P., Umbach, D. M., Resnick, M. A., Luzzatto, L., Inga, A., & Fronza, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2545 · Cited by 58 · see citing works

Mutant p53 protein in serum could be used as a molecular marker in human breast cancer

Balogh, G., Mailo, D., Corte-Torres, M. D., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.4.995 · Cited by 56 · see citing works

Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations

Suad, O., Rozenberg, H., Brosh, R., Diskin‐Posner, Y., Kessler, N., Shimon, L. J. W., Frolow, F., Liran, A., Rotter, V., & Shakked, Z. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.063 · Cited by 56 · see citing works

Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants

Yang, X., Pater, A., & Tang, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202843 · Cited by 50 · see citing works

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53

Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50 · see citing works

A low incidence of p53 mutations in pre‐malignant lesions of the oral cavity from non‐tobacco users

Lazarus, P. J., Garewal, H. S., Sciuuba, J., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600406 · Cited by 50 · see citing works

Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: Evidence that 15-lipoxygenase is a mutator gene

Kelavkar, U. P., & Badr, K. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4378 · Cited by 49 · see citing works

Breast-Cancer Stromal Cells withTP53Mutations

Campbell, I. G., Qiu, W., Polyák, K., & Haviv, I. (2008) · New England Journal of Medicine · doi:10.1056/nejmc086024 · Cited by 47 · see citing works

Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant.

Iwanaga, Y., & Jeang, K. (2002) · PubMed · Cited by 44 · see citing works

The versatile interactions of p53 with DNA: when flexibility serves specificity

Kim, E., & Deppert, W. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401909 · Cited by 44 · see citing works

TP53 gene mutations as an independent marker for urinary bladder cancer progression

Ecke, T., Sachs, M. D., Lenk, S. V., et al. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.5.655 · Cited by 42 · see citing works

Prognostic implications of circulating anti-p53 antibodies in lung cancer - a review

Kumar, S., Mohan, A., & Guleria, R. (2009) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2008.01019.x · Cited by 41 · see citing works

Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection

Mollevı́, D. G., Serrano, T., Ginesta, M. M., Valls, J., Torrás, J., Navarro, M., Ramos, E., Germà, J. R., Jaurrieta, E., Moreno, V. R., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm012 · Cited by 41 · see citing works

JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-?

Herr, I., Wilhelm, D., B�hler, T., Angel, P. E., & Debatin, K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990129)80:3 · Cited by 40 · see citing works

Functional analysis of p53 gene and the prognostic impact of dominant‐negative p53 mutation in endometrial cancer

Sakuragi, N., Watari, H., Ebina, Y., Yamamoto, R., Steiner, E., Koelbl, H., Yano, M., Tada, M., & Moriuchi, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21097 · Cited by 37 · see citing works

Gal‐3 is stimulated by gain‐of‐function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas

Lavra, L., Ulivieri, A., Rinaldo, C., Dominici, R., Volante, M., Luciani, E., Bartolazzi, A., Frasca, F., Soddu, S., & Sciacchitano, S. (2008) · The Journal of Pathology · doi:10.1002/path.2510 · Cited by 36 · see citing works

Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells

Tepper, C. G., Gregg, J. P., Shi, X.-B., et al. (2005) · The Prostate · doi:10.1002/pros.20308 · Cited by 35 · see citing works

Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo

Koga, H., & Deppert, W. (2000) · Oncogene · doi:10.1038/sj.onc.1203745 · Cited by 35 · see citing works

Mutant p53 Protects Cells from 12- O -Tetradecanoylphorbol-13-Acetate–Induced Death by Attenuating Activating Transcription Factor 3 Induction

Buganim, Y., Kalo, E., Brosh, R., Besserglick, H., Nachmany, I., Rais, Y., Stambolsky, P., Tang, X., Milyavsky, M., Shats, I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0916 · Cited by 34 · see citing works

Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression

Sänchez‐Carbayo, M., Socci, N. D., Richstone, L., Cortón, M., Behrendt, N., Wulkfuhle, J., Bochner, B. H., Petricoin, E. F., III, & Cordon‐Cardo, C. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070338 · Cited by 32 · see citing works

Transcriptional control of the proliferation cluster by the tumor suppressor p53

Brosh, R., & Rotter, V. (2009) · Molecular BioSystems · doi:10.1039/b911416e · Cited by 30 · see citing works

Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma

Chang, S., Lin, J.-K., Lin, T.-C., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.1.65 · Cited by 29 · see citing works

Evaluation of Arrayed Primer Extension for TP53 Mutation Detection in Breast and Ovarian Carcinomas

Kringen, P., Bergamaschi, A., Due, E. U., et al. (2005) · BioTechniques · doi:10.2144/000112000 · Cited by 26 · see citing works

Utilization of genomic signatures to direct use of primary chemotherapy

Potti, A., & Nevins, J. R. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.018 · Cited by 24 · see citing works

Breast-cancer stromal cells with TP53 mutations.

Zalcman, G., Bergot, E., & Hainaut, P. (2008) · PubMed · Cited by 23 · see citing works

Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: A long-term study

Sánchez, A. S. S., Lorenzo‐Romero, J. G., Bachs, J. M. G., et al. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.07.011 · Cited by 23 · see citing works

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis

Yang, Y. C., Lu, M. L., Rao, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603456 · Cited by 23 · see citing works

Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast

Keohavong, P., Gao, W., Mady, H. H., et al. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.010 · Cited by 22 · see citing works

Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours

Ryu, M., Kang, Y., Jang, S. J., Kim, T. W., Lee, H., Kim, J.-S., Park, Y. H., Lee, S. S., Ryoo, B., Chang, H. M., et al. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02797.x · Cited by 21 · see citing works

Prognostic and Predictive Value of TP53 Mutations in Human Cancer

Olivier, M., Hainaut, P. L., & Børresen-Dale, A.-L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_14 · Cited by 20 · see citing works

Oncogenomic Approaches in Exploring Gain of Function of Mutant p53

Donzelli, S., Biagioni, F., Fausti, F., Strano, S., Fontemaggi, G., & Blandino, G. (2008) · Current Genomics · doi:10.2174/138920208784340713 · Cited by 20 · see citing works

The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis

Sigal, A., Matas, D., Almog, N., Goldfinger, N., & Rotter, V. (2001) · Oncogene · doi:10.1038/sj.onc.1204724 · Cited by 19 · see citing works

The predictive value of p53 and p33ING1b in patients with Dukes'C colorectal cancer

Ahmed, I. A. M., Kelly, S. B., Anderson, J., et al. (2007) · Colorectal Disease · doi:10.1111/j.1463-1318.2007.01317.x · Cited by 17 · see citing works

Analysis of p53 Gene Alterations in Cancer: A Critical View

Soussi, T. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_12 · Cited by 13 · see citing works

Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection

Shi, H., Calvez‐Kelm, F. L., Olivier, M., & Hainaut, P. L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_13 · Cited by 9 · see citing works

TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas

Sahlberg, K. K., Diep, C. B., Pandis, N., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1812 · Cited by 9 · see citing works

TP53 mutations and codon 72 genotype—impact on survival among ovarian cancer patients

Wang, Y., Kristensen, G. B., Børresen-Dale, A. L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm134 · Cited by 7 · see citing works

biomarkers

(2008) · Annals of Oncology · doi:10.1093/annonc/mdn503 · Cited by 3 · see citing works

Detection of K-ras and p53 Gene Mutations in Pancreatic Juice for the Diagnosis of Intraductal Papillary Mucinous Tumors

Usui, H., & Otani, T. (2001) · Pancreas · doi:10.1097/00006676-200101000-00021 · Cited by 2 · see citing works

Untitled work

(2000) · doi:10.1002/1097-0215(20001015)88:2

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · see citing works

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works

Mutant p53 drives invasion by promoting integrin recycling

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796 · see citing works

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776 · see citing works

Telomeres: history, health, and hallmarks of aging

Chakravarti, D., LaBella, K. A., & DePinho, R. A. (2021) · Cell · doi:10.1016/j.cell.2020.12.028 · Cited by 637 · see citing works

The expanding universe of p53 targets

Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568 · see citing works

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308 · see citing works

Links between mutant p53 and genomic instability

Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216 · see citing works

Deconstructing p53 transcriptional networks in tumor suppression

Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194 · see citing works

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy333 · Cited by 197 · see citing works

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death &amp; Disease · doi:10.1038/cddis.2011.129 · Cited by 190 · see citing works

NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma

Zhao, S., Kurenbekova, L., Gao, Y., Roos, A., Creighton, C. J., Rao, P., Hicks, J., Man, T.-K., Lau, C., Brown, A. M. C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.429 · Cited by 139 · see citing works

p53 as a hub in cellular redox regulation and therapeutic target in cancer

Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · see citing works

p53 ancestry: gazing through an evolutionary lens

Lu, W.-J., Amatruda, J. F., & Abrams, J. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2732 · Cited by 112 · see citing works

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5

Vogiatzi, F., Brandt, D. T., Schneikert, J., Fuchs, J., Grikscheit, K., Wanzel, M., Pavlakis, E., Charles, J. P., Timofeev, O., Nist, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612711114 · Cited by 99 · see citing works

p53 at the crossroads between cancer and neurodegeneration

Lanni, C., Racchi, M., Memo, M., Govoni, S., & Uberti, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.034 · Cited by 95 · see citing works

NFκB/p53 crosstalk—a promising new therapeutic target

Schneider, G., & Krämer, O. H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.003 · Cited by 87 · see citing works

Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway

Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69 · see citing works

Molecular epidemiology of adrenocortical tumors in southern Brazil

Custódio, G., Komechen, H., Figueiredo, F. R. O., Fachin, N. D., Pianovski, M. A. D., & Figueiredo, B. C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.10.019 · Cited by 63 · see citing works

A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy

Huang, X., Zhang, Y., Tang, Y., Butler, N., Kim, J., Guessous, F., Schiff, D., Mandell, J., & Abounader, R. (2013) · Neoplasia · doi:10.1593/neo.13376 · Cited by 53 · see citing works

Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients

Pare, R., Soon, P. S., Shah, A., & Lee, C. S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214604 · Cited by 23 · see citing works

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Lanasa, M. C., Davis, P. H., Datto, M., Li, Z., Gockerman, J. P., Moore, J. O., DeCastro, C. M., Friedman, D. R., Diehl, L. F., Rehder, C., et al. (2012) · Leukemia &amp; Lymphoma · doi:10.3109/10428194.2011.610012 · Cited by 16 · see citing works

Transcriptome analysis of human ageing in male skin shows mid-life period of variability and central role of NF-κB

Haustead, D. J., Stevenson, A. W., Saxena, V., Marriage, F., Firth, M. J., Silla, R. C., Martin, L., Adcroft, K. F., Rea, S. M., Day, P. J., et al. (2016) · Scientific Reports · doi:10.1038/srep26846 · Cited by 59 · see citing works

Studying gene expression profiles in specialized brain regions by microSAGE

Vreugdenhil, E., & Datson, N. A. (2000) · doi:10.1093/oso/9780199637584.003.0009

Characterization of Early Developments in the Splenic Leukocyte Transcriptome of NOD Mice

Gerling, I., ALI, C., & Lenchik, N. I. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1288.017 · Cited by 5 · see citing works

Triplet Frequencies Implementation in Total Transcriptome Analysis

Sadovsky, M. G., Guseva, T., & Biriukov, V. V. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-17938-0_33

TRANSCRIPTOMIC AGING IN THE HRS

Thyagarajan, B. (2019) · Innovation in Aging · doi:10.1093/geroni/igz038.1612